Original Article

Detection of *SHOX* Gene Variations in Patients Who Had Skeletal Abnormalities With/Without Short Stature

Running Title: *SHOX* gene variations in patients with skeletal findings

Semra Gürsoy[1], Filiz Hazan[2], Ayça Aykut[3], Özlem Nalbantoğlu[4], Hüseyin Anıl Korkmaz[5], Korcan Demir[6], Behzat Özkan[4], Özgür Çogulu[7]

[1]Department of Pediatric Genetics, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

[2]Department of Medical Genetics, Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

[3]Department of Medical Genetics, Faculty of Medicine, Ege University, Izmir, Turkey.

[4]Department of Pediatric Endocrinology, Dr. Behcet Uz Children's Hospital, İzmir, Turkey.

[5]Department of Pediatric Endocrinology, Manisa City Hospital, Manisa, Turkey

[6]Department of Pediatric Endocrinology, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey.

[7]Department of Pediatric Genetics, Faculty of Medicine, Ege University, Izmir, Turkey.

What is already known on this topic?
The phenotypic spectrum of *SHOX* deficiency ranges from Langer mesomelic dysplasia at the severe end of the spectrum to idiopathic short stature at the mild end of the spectrum. Partial or whole *SHOX* gene deletions are usually detected in most of the patients.

What this study adds?
SHOX deficiency should be especially considered in patients who have disproportionate short stature or forearm anomalies with/without short stature. *SHOX* gene sequencing should be also performed in suspected patients who do not have any deletion/duplication in *SHOX* gene. Additionally, hearing loss might be accompanied to the skeletal and the other clinical features.

ABSTRACT
Objective: *SHOX* gene is one of the genetic causes of short stature and the clinical phenotype includes variable degrees of growth impairment such as Langer mesomelic dysplasia, Léri-Weill dyschondrosteosis or idiopathic short stature. In this study, we aimed to describe the clinical features and molecular results of *SHOX* deficiency in a group of Turkish patients who had skeletal findings with/without short stature.
Methods: Fourty-six patients with idiopathic short stature, disproportionate short stature or skeletal findings without short stature from 35 different families were included in the study. *SHOX* gene analysis was performed using Sanger sequencing and MLPA analysis.
Results: We detected three different point mutations (two nonsense, one frameshift) and one whole *SHOX* gene deletion in 15 patients from 4 different families. While 4 of 15 patients had Langer mesomelic dysplasia, the remaining patients had clinical features compatible with Léri-Weill dyschondrosteosis. Madelung's deformity, cubitus valgus, muscular hypertrophy and short forearm were the most common phenotypic features as well as short stature. Additionally, hearing loss was also detected in 2 patients with Langer mesomelic dysplasia.
Conclusion: In this study, we presented the clinical spectrum and molecular findings of 15 patients with *SHOX* gene mutations or deletions. *SHOX* deficiency should be especially considered in patients who have disproportionate short stature or forearm anomalies with/without short stature. Although most of the patients had a partial or whole gene deletions, *SHOX* gene sequencing should be performed in suspected cases. Furthermore, conductive hearing loss may rarely accompany these clinical manifestations.
Key Words: *SHOX* gene, short stature, MLPA, sequence analysis, Madelung's deformity, hearing loss

CORRESPONDING AUTHOR: Semra GÜRSOY
Department of Pediatric Genetics, Dr. Behcet Uz Children's Hospital,
İzmir, Turkey
Email: dr.semra@hotmail.com
Tel: +90 232 411 36 19
0000-0002-6795-3012
07.01.2020
25.03.2020

Introduction

Short stature is defined as a height more than 2 standard deviations (SDs) below the mean for age and sex, comparing to the national height standards, and affects 2%–3% of individuals in the general population. It is a multifactorial disorder as strong genetic and environmental factors are involved (1,2). Several monogenic genetic causes have been identified in short stature. One of these genes is the short stature homeobox-containing gene (*SHOX*) (3). The *SHOX* gene, which is located in pseudoautosomal region 1 (PAR1) on the short arm of the sex chromosomes Xp22.33 and Yp11.32, escapes X-inactivation. It encodes an important nuclear protein which acts as an important transcription factor during limb development (4,5).

The loss of both *SHOX* alleles causes an extreme phenotype of skeletal dysplasia called Langer mesomelic dysplasia (LMD) while *SHOX* haploinsufficiency is associated with a wide spectrum of short stature phenotypes including Turner syndrome, Léri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). LWD is characterized by short stature, mesomelic shortening of the limbs, and characteristic abnormality of the wrists known as Madelung's deformity. The phenotype can be also highly variable, even within the same family (6,7). The sensitivity of the clinical characteristics in identifying patients with ISS are usually insufficient, especially in younger children in whom skeletal disproportions are not so prominent (1,8). In many cases short stature is also the only clinical manifestation. Mutations or deletions of *SHOX* or *SHOX* regulatory regions have been detected in 75% of the cases with LMD and 60% of the cases with LWD. Additionally mutations of this gene are detected in 2-22% of ISS (9,10). However, partial or complete *SHOX* duplications have been described in a few patients with LWD and ISS (11). Moreover, more than 380 mutations in the coding regions of the gene and mutations in the downstream or upstream enhancer elements have been identified but a clear genotype-phenotype correlation has not been reported (1,12).

The aim of this study was to determine the clinical findings and molecular results of *SHOX* deficiency in a group of Turkish patients with LWD, LMD or ISS.

Methods

Patient Selection

Fourty-six patients with idiopathic short stature, disproportionate short stature or skeletal findings without short stature from 35 different families, who were examined at Department of Pediatric Genetics, Medical Genetics and Pediatric Endocrinology of Behçet Uz Child Disease and Pediatric Surgery Training and Research Hospital and Department of Medical Genetics of Ege University from Turkey, between June 2014 and July 2019, were included in this study. We recorded the age, sex, weight, height, body mass index (BMI), upper segment/lower segment ratios of 15 patients from 4 different families with *SHOX* gene variation. The clinical and dysmorphic features, anthropometric measurements, skeletal (e.g., appearance of muscular hypertrophy, cubitus valgus, forearm bowing, Madelung's deformity) and molecular findings were enrolled. Rappold scoring system was used and the results were calculated from the medical records of the patients. The score combines three anthropometric variables (arm span/height ratio, sitting height/height ratio and BMI), with five clinical variables (cubitus valgus, short forearm, bowing of forearm, muscular hypertrophy and dislocation of the ulna at the elbow), each of which represents at least two points in the score system. A score greater than 4 or 7 out of a total possible score of 24 is more valuable as a clinical indicator to detect patients with *SHOX* deficiency (1). Idiopathic short stature is defined as a condition characterized by a height more than 2 standard deviations below the mean of the age and sex-matched population with normal birth size, normal body proportions, normal nutrition no evidence of chronic disease, no psychiatric or emotional disturbance and no endocrine deficiency (13). The local Ethics Committee approved the study (Dr. Behcet Uz Children's Hospital, Clinical Research Ethics Committee, Izmir; Approval number: 2020/01-07), and written informed consent was obtained from all individuals involved.

Molecular Analysis

DNA isolation and Sanger sequencing

Genomic DNA from the peripheral blood lymphocytes of all individuals were extracted with Zinexts MagPurix Blood DNA Extraction Kit (Zinexts life science corp., New Taipei City, Taiwan) using standard procedures. All coding exons and exon-intron boundaries of *SHOX* gene were amplified by polymerase chain reaction. The sequences were evaluated using SeqScape Software 3 sequencing program (Applied Biosystems). "Ensembl.org" database (GRCh38.p12) with ENST00000381578.6 transcript ID of the *SHOX* gene was used to compare the individual's and the reference sequence. All variations were checked from mutation and SNP databases (Human Genome Mutation Database, National Center for Biotechnology Information, ensembl.org). Each variation was confirmed by bidirectional sequencing. Variation descriptions were done according to the nomenclature recommended by the Human Genomic Variation Society. Furthermore, in silico programmes, such as SIFT, PolyPhen 2, Mutation Taster were used to describe the pathogenity of novel variations in coding exons and exon-intron boundaries.

Multiplex ligation-dependent probe amplification (MLPA) analysis was performed to detect large deletions and duplications using P018 SALSA MLPA Kit (MRC-Holland, The Netherlands). The PCR products were analysed

by ABI 3500 capillary electrophoresis system and Coffalyser software. The area under the peak for each amplified fragment was measured and normalized to the peak areas of normal control individuals.

Results

Fourty-six patients from 35 families with short stature (idiopathic or disproportional) or skeletal findings without short stature were screened for deletions and intragenic mutations of the *SHOX* gene (Figure 1). We identified 15 patients from 4 different families; three different point mutations and one heterozygous whole *SHOX* gene deletion were detected (Table 1). The skeletal findings (cubitus valgus, Madelung's deformity, mesomelic shortening, radial bowing) of the mutation positive patients were variable even within the same family (Figure 2). The mean ± SD age of the patients with *SHOX* deletion/mutation at referral was 18.5 ± 14.4 years and five of them were male. Anthropometric parameters of the cases showed great variation in terms of clinical diagnosis. While the mean ± SD height SDS of the patients with LMD with severe Madelung deformity was -5.85±1.27, the mean ± SD height SDS of the patients with LWD was -1.7±1.76. The mean ± SD BMI of the fifteen patients with *SHOX* mutation/deletion was 23.7±5.5. The Rappold score, which was designed to identify the most appropriate patients for gene testing, was higher than 7 points in all of the patients with *SHOX* deficiency. The other clinical characteristics and molecular findings of the cases were detailed in Table 2. Patients with *SHOX* deficiency also showed significantly higher BMI SDS levels than patients without *SHOX* deficiency (BMI SDS 1.3±1.3 vs. -0,47±1.56, p <0.05). Furthermore, there was no significant difference between these two groups, regarding height and height SDS. The comparison of the demographic features of these two groups were shown in Table 3.

In the first family, a frameshift mutation, c.42delG (p.Ser16AlafsTer60), was detected in all family members (5 siblings and the parents). The parents had a consanguineous marriage. A 5 year-old boy and his 3 affected sisters were found to be homozygous for that mutation and were diagnosed with LMD. On the other hand, his brother and the parents were heterozygous for the same mutation, which favored the diagnosis of LWD. In physical examination disproportionate short stature, short and webbed neck, low hairline, pectus excavatus, bilateral severe Madelung's deformity with ulnar deviation, camptodactyly of the 3rd-4th digits in right hand and fourth digit in left hand were noted in the patients with LMD. Antero-posterior and lateral radiographs demonstrated the bowing and shortening of the distal radius, widening of the distal radial-ulnar joint, and triangulation of the distal radial epiphysis, producing an ulnar slant to the articular surface (Figure 2). Additionally, audiometric test showed that two of them had bilateral conductive hearing loss (Patient 1: right 45 dB, Left 45 dB. Patient 4: right 45 dB, Left 65 dB). Patient 5 had only Madelung's deformity, which was detected by radiological examination. Besides, the mother had short stature (142 cm) and Madelung's deformity and was diagnosed as LWD. We were not able to have contact with the father; we obtained related data from his photos and wife.

In the second family, a heterozygous nonsense mutation, c.631C>T (p.Q211X), was detected in a 7 year-old girl (Patient 8) who had the diagnosis of LWD. Her height was 113 cm (-1.63 SDS) and weight was 23 kg (0.03 SDS). Mild muscular hypertrophy, short forearm, bowing of the tibia were observed. Madelung deformity and cubitus valgus were not obvious. Her parents and two sisters were found to have similar clinical features and the same mutation. Additionally, the parents had cubitus valgus and Madelung deformity.

In the third family, Patient 13 and her father had an another heterozygous nonsense mutation, c.492G>A (p.W164X). This 12 year old girl was referred for multiple skeletal findings. Her height was 143 cm (-1.57 SDS) and mesomelic shortening was detected in upper and lower extremities. Madelung's deformity with pain and restriction of the flexion/extension were observed on the right forearm. In her radiologic examination, bowing of forearm, especially radial bowing, Madelung's deformity and ulnar shaft thickening were detected (Figure 2). Abdominal ultrasonography revealed right renal ptosis. Her father, who was 157 cm, had only short stature with mild mesomelic shortening.

Whole *SHOX* gene deletion was detected with MLPA analysis in patient 15 (the only member of the fourth family), who was referred for disproportional short stature. The patient was 14 years old and her height was 142 cm (-3.1 SDS). In her physical examination, cubitus valgus, bowing of the forearm, Madelung's deformity and short forearm were noticeable. Abdominal ultrasonography was normal. Karyotype analysis was 46,XX. The clinical features and molecular tests were also normal in other members of the family.

Discussion

In the present study, *SHOX* gene molecular defects in patients with LMD, LWD and ISS and the phenotype-genotype spectrum of *SHOX* deficiency were evaluated. In the current literature, point mutations and deletions of the *SHOX* gene have been reported in patients with ISS at an estimated prevalence ranging from 2-22% (9,10). Nevertheless, forearm anomalies and short stature with an increased sitting height/height ratio are most likely to be associated with *SHOX* haploinsufficiency (14,15).

The *SHOX* gene belongs to a family of transcriptional regulator which is essential for the development of the skeleton; especially in the growth and maturation of bones in the arms and legs (16). The clinical expression of *SHOX* deficiency is highly variable and the phenotype usually becomes more pronounced with age, and typical manifestations appear over time (17). While LMD, which is a much more severe skeletal dysplasia than LWD, results from biallelic (homozygous or compound heterozygous) *SHOX* pathogenic variants, *SHOX*

haploinsufficiency is associated with ISS and LWD (6). In the present study, 4 patients from the first family had a homozygous *SHOX* gene mutation and severe skeletal findings, whereas the clinical features of other family members, who had heterozygous mutation, were compatible with LWD. In the second family, the parents had more obvious skeletal manifestations than their daughters. Additionally, while the father of the patient 13 had only mild short forearm with short stature, the daughter had Madelung's deformity, radial bowing and ulnar shaft thickening in limb radiographies. Consistent with current literature, the clinical findings of these patients highlight an intrafamilial phenotypic variability.

In the present study, short stature, increased upper segment/lower segment ratio, short forearm, bowing of tibia and appearance of muscular hypertrophy were the most common phenotypic features in patients. Three out of four index patients had at least one affected family member. Additionally, in the first and the second family, the parents had a consanguineous marriage and both of them had a heterozygous mutation. As reported in the literature, it is not uncommon for patients with *SHOX* haploinsufficiency to have an affected parent (3).

The combination of dyschondrosteosis and hearing loss has been reported in several cases. In 1970 Nassif et al. (18), the authors described 5 siblings with dyschondrosteosis and two of the affected patients had a conductive hearing loss with middle ear deformities. The audiogram revealed bilateral conductive hearing loss of approximately 40-50 dB in both of the patients. In 2003, Leenheer et al. (19), reported a patient with a diagnosis of LWD who had a deletion in *SHOX* gene. The patient had short stature, mesomelic shortening and Madelung's deformity with shortening and bowing of the radius and dorsal dislocation of the ulnar head. The audiogram showed that the patient had an unilateral 35 dB conductive hearing loss in the left ear. In our study, bilateral conductive hearing loss was detected in two patients with LMD from the first family (Patient 1: right 45 dB, left 45 dB; Patient 4: right 45 dB, left 65 dB). Hearing tests were also normal in other affected siblings. On the basis of these findings, we suggest that conductive hearing loss may be a rare manifestation of *SHOX* deficiency and a hearing evaluation should be performed in these patients.

The most common mutation is the deletion of the partial or entire *SHOX* locus (i.e., 80–90% of cases), whereas point mutations appear to be less frequent (10–20%). The SHOX protein contains three characteristic domains: a homeodomain, an SH3 binding domain and an OAR domain. Most of the mutations have been described in the homeobox domain which spans exons 3 and 4. OAR domain is localized at the C terminal end of the gene and is essential for transactivation (11, 16). The homeodomain of *SHOX* gene mediates several key functions that include nuclear localization, DNA binding and protein–protein interactions; therefore, mutations located in this region may impair these processes and lead to bone defects (20). Furthermore, the cis-regulatory region of *SHOX* extends to ~ 1Mb of the PAR1 and alterations of these regions may be the cause of the phenotype (21). In the present study, whole *SHOX* gene deletion was detected in only 1 patient. Additionally, three different point mutations (two nonsense, one frameshift) were observed in 14 patients from 3 different families. Nonsense and frameshift mutations that lead to truncation of the SHOX protein can cause absence of the OAR domain at the C-terminal end, resulting in lack of transactivating function. In our study group, the first family had a heterozygous or homozygous frameshift mutation in exon 2, c.42delG (p.Ser16AlafsTer60), which caused the lack of the HD, SH3 and OAR domains. While the second family had a nonsense mutation, c.631C>T (p.Q211X), which was located in exon 5; an another nonsense mutation, c.492G>A (p.W164X), which was located in exon 4 and homeodomain region, was detected in the third family. Although the rate of gene deletions is high in *SHOX* deficiency, gene sequencing should be performed in suspected cases. There is also a wide range of phenotypic variations associated with mutations or deletions in the *SHOX* gene. In the current study, point mutations were detected in different exons, but no correlation was found between the severity of phenotype and the underlying *SHOX* pathogenic variant.

Study Limitations

The major limitation of our study is the relatively small size of the sample.

Conclusion

In conclusion, we described the clinical findings and molecular manifestations of 4 different *SHOX* alterations in 4 different families. Screening for *SHOX* deficiency should be considered in children with disproportionate short stature or forearm abnormalities with/without short stature. Furthermore, the fact that conductive hearing loss may accompany clinical manifestations should be kept in mind. The genetic diagnosis is essential for the management of the disease and prediction of prognosis. Future studies and identification of further *SHOX* modifier genes will allow better understanding of the phenotype–genotype correlation.

Authorship Contributions

Medical Practices: Semra Gürsoy, Filiz Hazan, Özlem Nalbantoğlu, Concept: Ayça Aykut, Korcan Demir, Özgür Çogulu, Design: Hüseyin Anıl Korkmaz, Behzat Özkan, Özgür Çogulu, Data Collection or Processing: Hüseyin Anıl Korkmaz, Korcan Demir, Semra Gürsoy, Filiz Hazan, Analysis or Interpretation: Ayça Aykut, Özgür Çogulu, Semra Gürsoy, Filiz Hazan, Literature Search: Ayça Aykut, Hüseyin Anıl Korkmaz, Behzat Özkan, Korcan Demir Writing: Behzat Özkan, Semra Gürsoy, Filiz Hazan, Özgür Çogulu.

Financial Disclosure: The authors declared that this study received no financial support.

REFERENCES

1.   Rappold G, Blum WF, Shavrikova EP, Crowe BJ, Roeth R, Quigley CA, et al. Genotypes and phenotypes in children with short stature: clinical indicators of SHOX haploinsufficiency. J Med Genet 2007;44:306-13.
2.   Morizio E, Stuppia L, Gatta V, Fantasia D, Guanciali Franchi P, Rinaldi MM, et al. Deletion of the SHOX gene in patients with short stature of unknown cause. Am J Med Genet A 2003;119:293-6.
3.   Jorge AA, Souza SC, Nishi MY, Billerbeck AE, Libório DC, Kim CA, et al. SHOX mutations in idiopathic short stature and Leri-Weill dyschondrosteosis: frequency and phenotypic variability. Clin Endocrinol 2007;66:130-5.
4.   Fukami M, Seki A, Ogata T. SHOX haploinsufficiency as a cause of syndromic and nonsyndromic short stature. Mol Syndromol 2016;7:3e11.
5.   Munns C, Haase HR, Crowther LM, Hayes MT, Blaschke R, Rappold G, et al. Expression of SHOX in human fetal and childhood growth plate. J Clin Endocrinol Metab 2004;89:4130–5.
6.   SHOX Deficiency Disorders. Binder G, Rappold GA. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. Binder G. Short stature due to SHOX deficiency: genotype, phenotype and therapy. Horm Res Paediatr 2011;75:81-9.
7.   Albuisson J, Schmitt S, Baron S, Bézieau S, Benito-Sanz S, Heath KE. Clinical utility gene card for: Leri-Weill dyschondrosteosis (LWD) and Langer mesomelic dysplasia (LMD). Eur J Hum Genet 2012;20(8).
8.   Wolters B, Lass N, Wunsch R, Böckmann B, Austrup F, Reinehr T. Short stature before puberty: which children should be screened for shox deficiency? Horm Res Paediatr 2013;80:273-80.
9.   Chen J, Wildhardt G, Zhong Z, Röth R, Weiss B, Steinberger D, et al. Enhancer deletions of the SHOX gene as a frequent cause of short stature: the essential role of a 250 kb downstream regulatory domain. J Med Genet. 2009;46:834–839.
10.   Rappold GA, Fukami M, Niesler B, Schiller S, Zumkeller W, Bettendorf M, et al. Deletions of the homeobox gene SHOX (short stature homeobox) are an important cause of growth failure in children with short stature. J Clin Endocrinol Metab. 2002;87:1402–1406.
11.   Benito-Sanz S, Barroso E, Heine-Suñer D, Hisado-Oliva A, Romanelli V, Rosell J, et al. Clinical and molecular evaluation of SHOX/PAR1 duplications in Leri-Weill dyschondrosteosis (LWD) and idiopathic short stature (ISS). J Clin Endocrinol Metab (2011) 96:404–12.10.1210/jc.2010-1689.
12.   Rosilio M, Huber-Lequesne C, Sapin H, Carel JC, Blum WF, Cormier-Daire V. Genotypes and phenotypes of children with SHOX deficiency in France. J Clin Endocrinol Metab 2012;97:E1257-65.
13.   Ranke MB. Towards a consensus on the definition of idiopathic short stature. Horm Res 1996;45(Suppl. 2):64e6.
14.   Hirschfeldova K, Solc R, Baxova A, Zapletalova J, Kebrdlova V, Gaillyova R, et al. SHOX gene defects and selected dysmorphic signs in patients of idiopathic short stature and Leri-Weill dyschondrosteosis. Gene 2012;491:123-7.
15.   Marstrand-Joergensen MR, Jensen RB, Aksglaede L, Duno M, Juul A. Prevalence of SHOX haploinsufficiency among short statured children. Pediatr Res 2017Feb;81(2):335-41. doi: 10.1038/pr.2016.233.
16.   Leka SK, Kitsiou-Tzeli S, Kalpini-Mavrou A, Kanavakis E. Short stature and dysmorphology associated with defects in the SHOX gene. Hormones (Athens) 2006;5(2):107-18.
17.   Delil K, Karabulut HG, Hacıhamdioğlu B, Şıklar Z, Berberoğlu M, Öçal G, et al. Investigation of SHOX Gene Mutations in Turkish Patients with Idiopathic Short Stature. J Clin Res Pediatr Endocrinol 2016Jun5;8(2):144-9. doi: 10.4274/jcrpe.2307.
18.   Nassif R, Harboyan G. Madelung's Deformity With Conductive Hearing Loss Arch Otolaryngol 1970;91(2):175-8.
19.   De Leenheer EM, Oudesluijs GG, Kuijpers-Jagtman AM, Rappold GA, Sengers RC, Cremers CW. Congenital conductive hearing loss in dyschondrosteosis. Ann Otol Rhinol Laryngol 2003;112(2):153-8.
20.   Lucchetti L, Prontera P, Mencarelli A, Sallicandro E, Mencarelli A, Cofini M, et al. Report of a Novel SHOX Missense Variant in a Boy With Short Stature and His Mother With Leri-Weill Dyschondrosteosis. Front Endocrinol (Lausanne) 2018Apr10;9:163. doi: 10.3389/fendo.2018.00163.
21.   Verdin H, Fernández-Miñán A, Benito-Sanz S, Janssens S, Callewaert B, Waele KD, et al. Profiling of conserved non-coding elements upstream of SHOX and functional characterisation of the SHOX cis-regulatory landscape. Sci Rep 2015;5:17667.

Table 1: The molecular details of the *SHOX* gene alterations.

Family No	Nucleotide Change	Aminoacid Change	Exon	Transmission	Phenotype in SHOX mutation database	Phenotype in the present Study
1	c.42delG	p.S16AfsTer60	2	Both of the parents were heterozygous	LWD	LMD, LWD
2	c.631C>T	p.Q211X	5	Both of the parents were heterozygous	ISS	LWD
3	c.492G>A	p.W164X	4	From the father	ISS	LWD
4	Whole gene deletion			-		LWD

LWD: Léri-Weill dyschondrosteosis**, ISS:** Idiopathic short stature**, PVS1:** Pathogenic Very Strong**, PM2:** Pathogenic Moderate**, PP3:** Pathogenic Supporting**, PM1:** Pathogenic Moderate**, SHOX mutation database:** LOVD X-chromosome gene database short stature homeobox
(http://grenada.lumc.nl/LOVD2/MR/home.php?select_db=SHOX).

Table 2: Clinical and molecular findings of the mutation/deletion positive patients.

Family No	Patient No	Age/Sex	Clinical Diagnosis	Height cm	Height SDS	BMI	BMI (SDS)	Upper segment/lower segment ratio	Madelung Deformity	Cubitus Valgus	Scoliosis	Muscular Hypertrophy	Rappold scoring results	Genetic Defects	Zygosity
1	1	14/F	LMD	115	-7.65	33.2	3.1	2.57 (>2SDS)	+ (severe)	+	-	+	19	c.42delG (p.Ser16AlafsTer60)	*Homozygous*
	2	9/M	LMD	102	-5.43	24.03	2.3	2.15 (>2SDS)	+ (severe)	+	-	+	19	c.42delG (p.Ser16AlafsTer60)	*Homozygous*
	3	8/F	LMD	102,2	-4.65	22.98	2.19	2.11 (>2SDS)	+ (severe)	+	-	+	19	c.42delG (p.Ser16AlafsTer60)	*Homozygous*
	4	6/F	LMD	88,6	-5.7	22.8	2.59	2.34 (>2SDS)	+ (severe)	+	-	+	19	c.42delG (p.Ser16AlafsTer60)	*Homozygous*
	5	2/M	LWD	86	-0.76	16.2	-0.15	NA	+ (mild)	-	-	+	14	c.42delG (p.Ser16AlafsTer60)	*Heterozygous*
	6 (Mother)	35/F	LWD	142	NA	26.7	NA	NA	+ (mild)	-	-	+	NA	c.42delG (p.Ser16AlafsTer60)	*Heterozygous*
	7 (Father)	36/M	LWD	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	c.42delG (p.Ser16AlafsTer60)	*Heterozygous*
2	8	7/F	LWD	113	-1,63	18.01	1.11	1.48 (>2SDS)	-	-	-	+	14	c.631C>T (p.Q211X)	*Heterozygous*
	9	9/F	LWD	123	-1.57	18.5	0.93	1.41 (>2SDS)	-	-	-	+	14	c.631C>T (p.Q211X)	*Heterozygous*
	10	9/F	LWD	123	-1.57	22.4	1.88	1.38 (>2SDS)	-	-	-	+	14	c.631C>T (p.Q211X)	*Heterozygous*
	11 (Father)	36/M	LWD	158	NA	28.4	NA	NA	+	+	-	+	NA	c.631C>T (p.Q211X)	*Heterozygous*
	12 (Mother)	36/F	LWD	154	NA	29.9	NA	1.26 (>2SDS)	+	+	-	+	16	c.631C>T (p.Q211X)	*Heterozygous*
3	13	12/F	LWD	143	-1.57	16.1	-1.21	1.11 (>2SDS)	+ (severe with pain)	+	-	+	13	c.492G>A (p.W164X)	*Heterozygous*
	14 (Father)	45/M	LWD	157	NA	31.2	NA	1.3 (>2SDS)	-	-	-	-	15	c.492G>A (p.W164X)	*Heterozygous*
4	15	14/F	LWD	142	-3.1	21.8	0.46	1.29 (>2SDS)	+	+	-	+	17	Whole gene deletion	*Heterozygous*

Table 3: Demographic and anthropometric findings of the patients with/without *SHOX* deficiency

Variable	SHOX	Non-SHOX	P value
Diagnosis (n)	15	31	
LMD	4	-	
LWD	11	-	
ISS	-	31	
Age (years)	18.5±14.4	12.45±8.9	0.24
n <18	10	27	
n >18	5	4	
Males/Females (%)	5 (33%)/10 (67%)	12 (39%)/19 (61%)	0,7
Height	124.9±24.8	122.7±19.7	0.77
Height (SDS)	-3.36±2.3	-2.8±1.0	0.93
BMI	23.7±5.5	18.7±5.5	0.005
BMI (SDS)	1.3±1.3	-0,47±1.56	0.004

Figure 1: This scheme provides an approach to the study design and molecular results of the patients with/without *SHOX* deficiency


Figure 2: The clinical and radiological findings of the mutation positive patients. A-E: The clinical features of the patients with LMD. F-G: Madelung deformity of Patient 15. H-I: Madelung deformity and short forearm of Patient 13. J: The direct radiography of Patient 2 revealed bowing and shortening of the distal radius, widening of the distal radial-ulnar joint, and triangulation of the distal radial epiphysis, producing an ulnar slant to the

articular surface. K: Bowing of forearm, radial bowing and ulnar shaft thickening of Patient 13.